4922 Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices 

These applications for review will be 

addressed in the future. Accordingly, 

this docket will remain open. 

10. Upon publication of document DA 

14–1871 in the Federal Register, these 

proceedings will be terminated in the 

Electronic Comment Filing System 

(ECFS). The record in the terminated 

proceedings will remain part of the 

Commission’s official records, and the 

various pleadings, orders, and other 

documents in these dockets will 

continue to be accessible to the public, 

post-termination. 

Regulatory Flexibility Act 

11. The Commission’s action does not 

require notice and comment and is not 

subject to the Regulatory Flexibility Act 

of 1980, as amended. See 5 U.S.C. 

601(2), 603(a). The Commission 

nonetheless notes that it anticipates that 

the rules adopted will not have a 

significant economic impact on a 

substantial number of small entities. As 

described above, the Commission 

primarily changes its own internal 

procedures and organizations and does 

not impose substantive new 

responsibilities on regulated entities. 

There is no reason to believe 

termination of certain dormant 

proceedings would impose significant 

costs on parties to Commission 

proceedings. To the contrary, the 

Commission takes the actions herein 

with the expectation that overall they 

will make dealings with the 

Commission quicker, easier, and less 

costly for entities of all size. 

Congressional Review Act 

The Commission will not send a copy 

of document DA 14–1871 pursuant to 

the Congressional Review Act, see 5 

U.S.C. 801(a)(1)(A) because the 

Commission is not adopting, amending, 

revising, or deleting any rules. 

Ordering Clauses 

Pursuant to the authority contained in 

sections 4(i), and 4(j) of the 

Communications Act, 47 U.S.C. 154(i) 

and (j), and § 0.141 of the Commission’s 

rules, that the proceedings set forth in 

document DA 14–1871 are terminated. 

Federal Communications Commission. 

Kris Anne Monteith, 

Acting Chief, Consumer and Governmental 

Affairs Bureau. 

[FR Doc. 2015–01702 Filed 1–28–15; 8:45 am] 

BILLING CODE 6712–01–P 

FEDERAL MINE SAFETY AND HEALTH 

REVIEW COMMISSION 

Sunshine Act Notice 

January 26, 2015. 

TIME AND DATE: 2:00 p.m., Thursday, 

January 29, 2015. 

PLACE: The Richard V. Backley Hearing 

Room, Room 511N, 1331 Pennsylvania 

Avenue NW., Washington, DC 20004 

(enter from F Street entrance). 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: It was 

determined by a unanimous vote of the 

Commissioners that the Commission 

consider and act upon the following in 

closed session: Brody Mining, LLC v. 

Secretary of Labor, Docket Nos. WEVA 

2014–82–R, et al. (Issues include 

whether to grant or deny the Secretary 

of Labor’s Emergency Motion for Stay of 

ALJ’s Order Dismissing Pattern-ofViolations Notice.) This is the earliest 

practicable time that notice of the closed 

meeting could be provided. 

CONTACT PERSON FOR MORE INFO: 

Emogene Johnson (202) 434–9935/(202) 

708–9300 for TDD Relay/1–800–877– 

8339 for toll free. 

Sarah L. Stewart, 

Deputy General Counsel. 

[FR Doc. 2015–01726 Filed 1–27–15; 11:15 am] 

BILLING CODE 6735–01–P 

FEDERAL MINE SAFETY AND HEALTH 

REVIEW COMMISSION 

Sunshine Act Meeting 

January 27, 2015. 

TIME AND DATE: 11:00 a.m., Thursday, 

February 5, 2015. 

PLACE: The Richard V. Backley Hearing 

Room, Room 511N, 1331 Pennsylvania 

Avenue NW., Washington, DC 20004 

(enter from F Street entrance). 

STATUS: Open. 

MATTERS TO BE CONSIDERED: The 

Commission will consider and act upon 

the following in open session: Mill 

Branch Coal Corp. v. Secretary of Labor, 

Docket Nos. VA 2012–435–R et al. 

(Issues include whether the 

Administrative Law Judge erred in 

upholding an imminent danger order.) 

Any person attending this meeting 

who requires special accessibility 

features and/or auxiliary aids, such as 

sign language interpreters, must inform 

the Commission in advance of those 

needs. Subject to 29 CFR 2706.150(a)(3) 

and 2706.160(d). 

CONTACT PERSON FOR MORE INFO: 

Emogene Johnson (202) 434–9935/(202) 

708–9300 for TDD Relay/1–800–877– 

8339 for toll free. 

Sarah L. Stewart, 

Deputy General Counsel. 

[FR Doc. 2015–01808 Filed 1–27–15; 4:15 pm] 

BILLING CODE 6735–01–P 

FEDERAL MINE SAFETY AND HEALTH 

REVIEW COMMISSION 

Sunshine Act Meeting 

January 27, 2015. 

TIME AND DATE: 10:00 a.m., Thursday, 

February 5, 2015. 

PLACE: The Richard V. Backley Hearing 

Room, Room 511N, 1331 Pennsylvania 

Avenue NW., Washington, DC 20004 

(enter from F Street entrance). 

STATUS: Open. 

MATTERS TO BE CONSIDERED: The 

Commission will consider and act upon 

the following in open session: Secretary 

of Labor v. Jim Walter Resources, Inc., 

Docket No. SE 2011–407–R; and 

Secretary of Labor v. Jim Walter 

Resources, Inc., Docket No. SE 2012– 

681–R (Issues include whether the 

Administrative Law Judges erred in 

upholding certain imminent danger 

orders.) 

Any person attending this meeting 

who requires special accessibility 

features and/or auxiliary aids, such as 

sign language interpreters, must inform 

the Commission in advance of those 

needs. Subject to 29 CFR 2706.150(a)(3) 

and 2706.160(d). 

CONTACT PERSON FOR MORE INFO: 

Emogene Johnson (202) 434–9935/(202) 

708–9300 for TDD Relay/1–800–877– 

8339 for toll free. 

Sarah L. Stewart, 

Deputy General Counsel. 

[FR Doc. 2015–01805 Filed 1–27–15; 4:15 pm] 

BILLING CODE 6735–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Advisory Committee on 

Blood and Tissue Safety and 

Availability 

AGENCY: Department of Health and 

Human Services, Office of the Secretary, 

Office of the Assistant Secretary for 

Health. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Services is hereby giving notice that the 

Advisory Committee on Blood and 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices 4923 

Tissue Safety and Availability 

(ACBTSA) will hold a meeting. The 

meeting will be open to the public. 

DATES: The meeting will take place 

Tuesday April 7, 2105, from 8:00 a.m.– 

4:00 p.m. and Wednesday April 8, 2015, 

from 8:00 a.m.–3:30 p.m. 

ADDRESSES: NIH Conference Room, 5635 

Fishers Lane, Rockville, MD 20892. 

FOR FURTHER INFORMATION CONTACT: Mr. 

James Berger, Designated Federal Officer 

for the ACBTSA, Senior Advisor for 

Blood and Tissue Policy, Office of the 

Assistant Secretary for Health, 

Department of Health and Human 

Services, 1101 Wootton Parkway, Suite 

250, Rockville, MD 20852. Phone: (240) 

453–8803; Fax (240) 453–8456; Email 

ACBTSA@hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

ACBTSA provides advice to the 

Secretary through the Assistant 

Secretary for Health. The Committee 

advises on a range of policy issues to 

include: (1) Identification of public 

health issues through surveillance of 

blood and tissue safety issues with 

national biovigilance data tools; (2) 

identification of public health issues 

that affect availability of blood, blood 

products, and tissues; (3) broad public 

health, ethical and legal issues related to 

the safety of blood, blood products, and 

tissues; (4) the impact of various 

economic factors (e.g., product cost and 

supply) on safety and availability of 

blood, blood products, and tissues; (5) 

risk communications related to blood 

transfusion and tissue transplantation; 

and (6) identification of infectious 

disease transmission issues for blood, 

organs, blood stem cells and tissues. 

The Committee has met regularly since 

its establishment in 1997. 

The ACBTSA has made previous 

recommendations on the need to 

improve tissue tracking and traceability. 

These recommendations focused on 

tracking adverse events, creating a 

unique identifier for each donor, and 

improving patient outcomes. Past 

recommendations made by the ACBTSA 

may be viewed at www.hhs.gov/

bloodsafety. 

The focus of the meeting will be to 

address current issues in tracking and 

traceability of tissue recovered from 

deceased donors. The discussion will 

focus on pertinent federal and state 

regulations, other mechanisms that 

impact tissue tracking and traceability, 

and current gaps in this area. Presenters 

will represent a wide range of 

government and non-government 

stakeholders, including federal agencies, 

accreditation organizations, tissue and 

eye banks, healthcare facilities, and 

medical practitioners. 

The public will have an opportunity 

to present their views to the Committee 

during a public comment session 

scheduled for April 8, 2015. Comments 

will be limited to five minutes per 

speaker and must be pertinent to the 

discussion. Pre-registration is required 

for participation in the public comment 

session. Any member of the public who 

would like to participate in this session 

is encouraged to contact the Designated 

Federal Officer at his/her earliest 

convenience to register for time (limited 

to 5 minutes) ; registration must be 

completed prior to close of business on 

April 1, 2015. If it is not possible to 

provide 30 copies of the material to be 

distributed at the meeting, then 

individuals are requested to provide a 

minimum of one (1) copy of the 

document(s) to be distributed prior to 

the close of business on April 1, 2015. 

It is also requested that any member of 

the public who wishes to provide 

comments to the Committee utilizing 

electronic data projection submit the 

necessary material to the Designated 

Federal Officer prior to the close of 

business on April 1, 2015. 

Dated: January 22, 2015. 

James J. Berger, 

Senior Advisor for Blood and Tissue Safety 

Policy. 

[FR Doc. 2015–01680 Filed 1–28–15; 8:45 am] 

BILLING CODE 4150–41–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Nominations to the Advisory 

Committee on Blood and Tissue Safety 

and Availability 

AGENCY: Office of the Secretary, Office 

of the Assistant Secretary for Health, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: The Office of Assistant 

Secretary for Health (OASH) is seeking 

nominations of qualified individuals to 

be considered for appointment as 

members of the Advisory Committee on 

Blood and Tissue Safety and 

Availability (ACBTSA). ACBTSA is a 

Federal advisory committee within the 

Department of Health and Human 

Services. Management support for the 

activities of this Committee is the 

responsibility of the OASH. The 

qualified individuals will be nominated 

to the Secretary of Health and Human 

Services for consideration of 

appointment as members of the 

ACBTSA. Members of the Committee, 

including the Chair, are appointed by 

the Secretary. Members are invited to 

serve on the Committee for up to fouryear terms. 

DATES: All nominations must be 

received no later than 4:00 p.m. EDT on 

March 2, 2015, at the address listed 

below. 

ADDRESSES: All nominations should be 

mailed or delivered to Mr. James Berger, 

Senior Advisor for Blood and Tissue 

Policy; Office of Assistant Secretary for 

Health; Department of Health and 

Human Services; 1101 Wootton 

Parkway, Suite 250; Rockville, MD 

20852. Telephone: (240) 453–8803; Fax 

(240) 453–8456; Email ACBTSA@

hhs.gov. 

FOR FURTHER INFORMATION CONTACT: Mr. 

James Berger, Senior Advisor for Blood 

and Tissue Policy. Contact information 

for Mr. Berger is provided above. 

A copy of the Committee charter and 

roster of the current membership can be 

obtained by contacting Mr. Berger or by 

accessing the ACBTSA Web site at 

http://www.hhs.gov/bloodsafety. http://

www.hhs.gov/bloodsafety. 

SUPPLEMENTARY INFORMATION: The 

ACBTSA shall provide advice to the 

Secretary through the Assistant 

Secretary for Health. The Committee 

shall advise on a range of policy issues 

to include: (1) Identification of public 

health issues through surveillance of 

blood and tissue safety issues with 

national biovigilance data tools; (2) 

identification of public health issues 

that affect availability of blood, blood 

products, and tissues; (3) broad public 

health, ethical and legal issues related to 

the safety of blood, blood products, and 

tissues; (4) the impact of various 

economic factors (e.g., product cost and 

supply) on safety and availability of 

blood, blood products, and tissues; (5) 

risk communications related to blood 

transfusion and tissue transplantation; 

and (6) identification of infectious 

disease transmission issues for blood, 

organs, blood stem cells and tissues. 

The Committee consists of 23 voting 

members. The Committee composition 

includes 14 public members, including 

the Chair, and nine (9) individuals 

designated to serve as official 

representative members. The public 

members are selected from state and 

local organizations, patient advocacy 

groups, provider organizations, 

academic researchers, ethicists, 

physicians, surgeons, scientists, risk 

communication experts, consumer 

advocates, and from among 

communities of persons who are 

frequent recipients of blood or blood 

products or who have received tissues 

or organs. The nine individuals who are 

appointed as official representatives are 

mstockstill on DSK4VPTVN1PROD with NOTICES